Skye Bioscience to Present at Benzinga Biotech Small Cap Conference
March 18, 2021 08:45 ET
|
Skye Bioscience, Inc.
San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment
March 16, 2021 08:30 ET
|
Skye Bioscience, Inc.
San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board
March 08, 2021 08:39 ET
|
Skye Bioscience, Inc.
San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference
March 03, 2021 08:37 ET
|
Skye Bioscience, Inc.
San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Skye Bioscience to Participate in Investment Conferences in February
February 03, 2021 09:09 ET
|
Skye Bioscience, Inc.
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience
January 19, 2021 08:30 ET
|
Skye Bioscience, Inc.
San Diego, Calif, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th
January 15, 2021 13:30 ET
|
Emerald Bioscience, Inc.
San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary,...
Emerald Bioscience to Present at the KCSA Cannabis Investor Conference
January 05, 2021 08:30 ET
|
Emerald Bioscience, Inc.
San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary...
Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of THCVHS is Published in Peer-Reviewed Journal
December 16, 2020 08:30 ET
|
Emerald Bioscience, Inc.
Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma San...
Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference
December 07, 2020 08:45 ET
|
Emerald Bioscience, Inc.
San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on developing...